OncoSil Medical Limited (OSL.AX)
AUD 0.01
(-14.29%)
AUD 0.01
(-14.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 55.63 Thousand AUD | 100.86% |
| 2023 | -6.49 Million AUD | 3.46% |
| 2022 | -6.72 Million AUD | -8.02% |
| 2021 | -6.22 Million AUD | -338.18% |
| 2020 | 2.61 Million AUD | -27.12% |
| 2019 | 3.58 Million AUD | -18.61% |
| 2018 | 4.4 Million AUD | 26.47% |
| 2017 | 3.48 Million AUD | -8.67% |
| 2016 | 3.81 Million AUD | 38.4% |
| 2015 | 2.75 Million AUD | 772.92% |
| 2014 | 315.85 Thousand AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | -100.0% |
| 2010 | 749.88 Thousand AUD | -11.11% |
| 2009 | 843.63 Thousand AUD | -13.75% |
| 2008 | 978.11 Thousand AUD | 22.57% |
| 2007 | 797.97 Thousand AUD | -16.43% |
| 2006 | 954.9 Thousand AUD | 0.0% |
| 2005 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | -5.79 Million AUD | 10.76% |
| 2024 Q2 | -3.22 Million AUD | 0.0% |
| 2024 Q4 | -2.61 Million AUD | 0.0% |
| 2023 FY | -6.49 Million AUD | 3.46% |
| 2023 Q4 | -3.42 Million AUD | 0.0% |
| 2023 Q2 | -3.06 Million AUD | 0.0% |
| 2022 FY | -6.72 Million AUD | -8.02% |
| 2022 Q2 | -3.22 Million AUD | 0.0% |
| 2022 Q4 | -3.19 Million AUD | 0.0% |
| 2021 Q4 | -3.84 Million AUD | 0.0% |
| 2021 Q2 | -2.38 Million AUD | 0.0% |
| 2021 FY | -6.22 Million AUD | -338.18% |
| 2020 Q4 | 1.51 Million AUD | 0.0% |
| 2020 FY | 2.61 Million AUD | -27.12% |
| 2020 Q2 | 1.09 Million AUD | 0.0% |
| 2019 FY | 3.58 Million AUD | -18.61% |
| 2019 Q4 | 1.81 Million AUD | 0.0% |
| 2019 Q2 | 1.81 Million AUD | 0.0% |
| 2018 Q4 | 2.64 Million AUD | 0.0% |
| 2018 FY | 4.4 Million AUD | 26.47% |
| 2018 Q2 | 1.8 Million AUD | 0.0% |
| 2017 Q2 | 900 Thousand AUD | 0.0% |
| 2017 FY | 3.48 Million AUD | -8.67% |
| 2017 Q4 | 2.61 Million AUD | 0.0% |
| 2016 FY | 3.81 Million AUD | 38.4% |
| 2016 Q2 | 2.5 Million AUD | 0.0% |
| 2016 Q4 | 1.33 Million AUD | 0.0% |
| 2015 FY | 2.75 Million AUD | 772.92% |
| 2015 Q4 | 1.5 Million AUD | 0.0% |
| 2015 Q2 | 1.25 Million AUD | 0.0% |
| 2014 Q4 | 315.85 Thousand AUD | 0.0% |
| 2014 FY | 315.85 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q1 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q1 | 187.47 Thousand AUD | -0.0% |
| 2011 Q3 | - AUD | 0.0% |
| 2011 FY | - AUD | -100.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | -100.0% |
| 2010 Q3 | 187.47 Thousand AUD | -0.0% |
| 2010 Q2 | 187.47 Thousand AUD | -11.11% |
| 2010 FY | 749.88 Thousand AUD | -11.11% |
| 2010 Q4 | 187.47 Thousand AUD | 0.0% |
| 2010 Q1 | 210.9 Thousand AUD | 0.0% |
| 2009 FY | 843.63 Thousand AUD | -13.75% |
| 2009 Q4 | 210.9 Thousand AUD | 0.0% |
| 2009 Q1 | 260.18 Thousand AUD | 0.0% |
| 2009 Q2 | 210.9 Thousand AUD | -18.94% |
| 2009 Q3 | 210.9 Thousand AUD | 0.0% |
| 2008 Q2 | 260.18 Thousand AUD | 16.19% |
| 2008 Q1 | 223.93 Thousand AUD | 0.0% |
| 2008 FY | 978.11 Thousand AUD | 22.57% |
| 2008 Q4 | 260.18 Thousand AUD | 0.0% |
| 2008 Q3 | 260.18 Thousand AUD | 0.0% |
| 2007 Q4 | 223.93 Thousand AUD | 0.0% |
| 2007 Q2 | 223.93 Thousand AUD | -6.2% |
| 2007 Q1 | 238.72 Thousand AUD | 0.0% |
| 2007 FY | 797.97 Thousand AUD | -16.43% |
| 2007 Q3 | 223.93 Thousand AUD | 0.0% |
| 2006 FY | 954.9 Thousand AUD | 0.0% |
| 2006 Q4 | 238.72 Thousand AUD | 0.0% |
| 2006 Q2 | 238.72 Thousand AUD | 0.0% |
| 2006 Q1 | - AUD | 0.0% |
| 2006 Q3 | 238.72 Thousand AUD | 0.0% |
| 2005 FY | - AUD | 0.0% |
| 2005 Q3 | - AUD | 0.0% |
| 2005 Q2 | - AUD | 0.0% |
| 2005 Q4 | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| 4DMedical Limited | 3.51 Million AUD | 98.418% |
| Adherium Limited | -640.83 Thousand AUD | 108.681% |
| Aroa Biosurgery Limited | 53.98 Million AUD | 99.897% |
| Atomo Diagnostics Limited | 1.43 Million AUD | 96.128% |
| Anteris Technologies Ltd | 2.51 Million AUD | 97.79% |
| Control Bionics Limited | 3.67 Million AUD | 98.485% |
| CardieX Limited | 10.1 Million AUD | 99.45% |
| Compumedics Limited | 26.06 Million AUD | 99.787% |
| Cochlear Limited | 1.69 Billion AUD | 99.997% |
| CleanSpace Holdings Limited | 11.35 Million AUD | 99.51% |
| Cyclopharm Limited | 4.49 Million AUD | 98.763% |
| EMVision Medical Devices Ltd | 11.21 Million AUD | 99.504% |
| Nova Eye Medical Limited | 20.19 Million AUD | 99.724% |
| HeraMED Limited | -504.09 Thousand AUD | 111.036% |
| Imricor Medical Systems, Inc. | -1.99 Million AUD | 102.792% |
| ImpediMed Limited | 9 Million AUD | 99.382% |
| InhaleRx Limited | 1.2 Million AUD | 95.38% |
| LBT Innovations Limited | -2.91 Million AUD | 101.907% |
| Micro-X Limited | 5.73 Million AUD | 99.03% |
| Neurotech International Limited | -5867.00 AUD | 1048.219% |
| PolyNovo Limited | 36.08 Million AUD | 99.846% |
| Respiri Limited | 456.91 Thousand AUD | 87.824% |
| SomnoMed Limited | 55.13 Million AUD | 99.899% |
| Universal Biosensors, Inc. | 4.28 Million AUD | 98.702% |
| Uscom Limited | 3.11 Million AUD | 98.214% |
| Visioneering Technologies, Inc. | -271.11 Thousand AUD | 120.52% |